Menu Close

60 Degrees Pharmaceuticals

Description

60° Pharmaceuticals (60P) was founded in 2010 with a mission to realize new ways to improve and extend people’s lives by discovering, developing, and distributing new best-in-class medicines for the treatment and prevention of tropical diseases. The Company is now developing and commercializing products more broadly for infectious disease.

60 Degrees Pharmaceuticals, LLC manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries.

60° Pharmaceuticals (60P) was founded with the goal of developing medicines for tropical diseases, including those considered neglected by the World Health Organization. In 2018, we took a huge step toward meeting our goals when our first product was approved for use by the US Food and Drug Administration.

ARAKODA® (tafenoquine) is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older.

Important Safety Information

Contraindications 
ARAKODA® should not be administered to:

  • G6PD deficiency or unknown G6PD status
  • Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown
  • Patients with a history of psychotic disorders or current psychotic symptoms
  • Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®

Warnings and Precautions

  • Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.
  • G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD status before breastfeeding begins.
  • Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.
  • Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and, evaluation by a mental health professional as soon as possible.
  • Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.
  • Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 17 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration.

Adverse Reactions 
The most common adverse reactions (incidence ≥1%) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams and anxiety.

Drug Interactions 
Avoid co-administration with drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters.

Use in Specific Populations 
Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®.

To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals at 1-888-834-0225 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

60 Degrees Pharmaceuticals, LLC
1025 Connecticut Avenue NW
Suite 1000
Washington, D.C. 20036
Phone: (202) 327-5422Website: https://60degreespharma.com/

Leave a Reply

Please leave correct email if you want us to contact you

Your email address will not be published. Required fields are marked *